AstraZeneca : Opening session

Capital markets event

Meet AZN management: ASCO 2020

Pascal Soriot, Dave Fredrickson, José Baselga

IR moderator: Thomas Kudsk Larsen

1 June 2020

Webinar is being recorded

Forward-looking statements disclaimer

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

Agenda

Introduction and overviewOncology strategy and growthASCO 2020 highlights

• -Tagrissoadjuvant lung cancer (ADAURA trial)

• -Imfinzismall cell lung cancer (CASPIAN trial)

• -Enhertugastric, lung and colorectal cancers (DESTINY trials)

Virtual breakout sessions

Meet AZN management: ASCO 2020

Four Q&A-focused, virtual breakout sessions

Tagrissoand immuno-oncology

Session 1: 16:35 BST Session 2: 17:15 BST

Dave Fredrickson, Cristian Massacesi

https://astrazeneca.zoom.us/webinar/register/WN_-ScpPmA9TRST-5NET3fEig

Webinar ID: 936 3943 3037

IR moderator:[e-mail]

Pascal Soriot, Dave Fredrickson, José Baselga

Opening session

16:00-16:25 BST

https://astrazeneca.zoom.us/webinar/register/WN_hEt-K5tqRGOxefPVfBtTdgWebinar ID: 957 3417 3925 | IR moderator:[e-mail]

Enhertuand breast cancer

Session 1: 16:35 BST Session 2: 17:15 BST

José Baselga, Mika Sovak, Jon Wildin

https://astrazeneca.zoom.us/webinar/register/WN_Mux3EqBhTmeTmtJ-UuhVYA

Webinar ID: 995 5382 4818

IR moderator:[e-mail]

Lynparza

Session 1: 16:35 BST Session 2: 17:15 BST

Susan Galbraith,

Greg Rossi

https://astrazeneca.zoom.us/webinar/register/WN_gvp6EHQ6TW2i9LikUbrx3Q

Webinar ID: 989 7940 1118

IR moderator:[e-mail]

Calquenceand haematology

Session 1: 16:35 BST Session 2: 17:15 BST

Michelle Werner, Andrew Mortlock

https://astrazeneca.zoom.us/webinar/register/WN_Tx4eYAyFSxi4nQ2x8iMkNA

Webinar ID: 933 8283 0734

IR moderator:[e-mail]

If you cannot connect using Zoom Webinar on a computer or device, please use the following phone details: [phone] | [phone] | [phone], including the appropriate Webinar ID

Event closes c. 17:45 BST

103 presented abstracts 26% increase over 2019

Plenary presentation

Oral presentationPoster discussion

20192020

Poster

Source: ASCO 2020 accepted abstracts. A total of 132 abstracts were accepted of which 29 abstracts were selected for publication only.

Data highlights

• •Tagrisso

  Phase III ADAURA - adjuvant lung

  cancer (plenary, late-breaking

  abstract)

• •Imfinzi

  Phase III CASPIAN - extensive-stage small cell lung cancer

• •Enhertu

  Phase II trials in gastric, lung and

  colorectal cancers and update in

  breast cancer